Humanized Mice Model Market | Contrive Datum Insights

Global Humanized Mice Model Market size was valued at USD 95.72 Million in 2022 and is projected to reach USD 188.57 Million by 2030, growing at a CAGR of 9.54% from 2022 to 2030.

Humanized Mice Model Market Overview:

Fruit purees have often been replaced by imitation products and low-standard fruit purees, some of which have been noticed and banned worldwide in recent years. Consumer anxiety about the origin of raw fruit has been a focus, and consumers are willing to pay much more to get genuine products.

Some manufacturers have responded to consumer demand by improving the traceability of their products by coding them and creating traceability to specific farms around the world. This has resulted in a wide range of applications for certain fruit pureed products, one of which is avocado puree.

The humanized mouse is a mouse that possesses functioning human genes, cells, tissues, and/or organs in the case of biological and medical research for human therapeutics. These mouse models are used to model the human immune system in scenarios of health and pathology. Humanized mouse models are used for basic research, safety assessment for large molecule therapeutics, modeling of certain human-specific infectious diseases, and efficacy testing of immunotherapy approaches. The human protein is expressed while the mouse protein is suppressed in all cells and tissues. Humanized mouse models are important tools required to conduct preclinical research, mimic human pathological conditions, test compound efficacy, and measure its effects on human proteins.

The model requires accurate risk assessment and thorough analysis to preserve the physiological expression and regulation of the human gene inserted into the mouse genome. In order to determine the optimal expression and functionality of the human protein in a mouse environment, the genes and proteins of both, the mouse and human, are analyzed for accuracy and structure. Humanized mouse models are used in biomedical research including cancer biology, regenerative medicine, human hematopoiesis, infectious diseases, transplantation, and autoimmunity.

Key Market Updates:

• In September 2021, genOway, a biotechnology company dedicated to the design and development of preclinical models, announced the acquisition of Axenis, a company dedicated to developing immunocompromised models for validation of new and innovative therapeutics.
• In January 2022, Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announced the release of the huNOG-EXL Early Access (EA) humanized immune system (HIS) mouse. This product expands Taconic's widely used HIS portfolio. The huNOG-EXL EA significantly extends the duration of studies in which myeloid lineage HIS mouse models can be successfully used.
• In October 2021, The Jackson Laboratory (JAX), a non-profit biomedical research organization based in the US, announced that it would acquire Charles River Laboratories Japan's Research Models & Services (RMS) business as a wholly owned subsidiary. The Japan-based organization, which will be named Jackson Laboratory Japan, has approximately 250 employees and three production facilities in Atsugi, Hino and Tsukuba and a management office in Yokohama.

Major Market Segments Covered in Humanized Mice Model Market Industry Research:

Market Key Players:

• Ingenious Targeting Laboratory
• Axen
• rans Genic Inc.
• Horizon Discovery Group PLC
• HuMurine Technologies
• Champions Oncology Inc.
• Trans Genic Inc.
• Crown Bioscience Inc.
• Others.

Key Vendors:

1.Ingenious Targeting Laboratory: It is a global provider of gene targeting and custom mouse model production services. With over two decades in the industry, ingenious has created and delivered over 2,000 custom mouse models to investigators worldwide. ingenious serves academic and medical institutes, government research centers, and pharmaceutical and biotechnology companies. Clients retain full intellectual property rights to their projects.

2.Horizon Discovery Group PLC:Its company, drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine.

3.Champions Oncology Inc.:It provides an end-to-end range of research and development solutions and services that improve the productivity of oncology drug development. Using both in vitro to in vivo testing platforms companies can leverage the expertise at Champions Oncology to help guide decision making for clinical development scenarios. From screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.

4.Trans Genic Inc.:It is a biotechnology company that develops and distributes genetically engineered animals and antibodies and licensing of these activities. The company’s product portfolio and services include knockout mouse and phenotype database, custom production of antibodies and proteins, genetically engineered mice, custom production of knock out mouse, drug discovery and contract services for non-clinical study, support services, mouse related products and antibody related products.

5.Crown Bioscience Inc.: A JSR Life Sciences company, is a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology, immuno-oncology, and immune-mediated inflammatory diseases. Known for their high quality and expansive in vivo, in vitro and ex vivo preclinical models, they partner with their clients to quantify the efficacy and pharmacological profile of their drug candidate before they move into the clinic.

By Type:

• Humanized Mouse Models
• Humanized Rat Models

Humanized mouse models are typically created by transplanting human cells or tissues into immunodeficient mice. This allows the human cells to engraft and survive in the mouse body, providing a more accurate model of human disease. Humanized mouse models are often used to study cancer, autoimmune diseases, and infectious diseases.

Humanized rat models are less common than humanized mouse models, but they offer some advantages. Rats are larger than mice, which allows for more precise measurements of disease progression. Rats also have a longer lifespan, which can be important for studying chronic diseases. Humanized rat models are often used to study neurodegenerative diseases and cardiovascular diseases.

By Application:

• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic & Research Institutions

Pharmaceutical and biotechnology companies are the primary users of humanized mouse models. They use these models to study the efficacy and safety of new drugs and treatments, as well as to develop new drug targets. The humanized mouse model market is expected to grow significantly in the coming years, as more pharmaceutical and biotechnology companies adopt these models in their research.

Contract research organizations (CROs) also play a significant role in the humanized mouse model market. CROs provide a variety of services to pharmaceutical and biotechnology companies, including the development and maintenance of humanized mouse models. CROs can help pharmaceutical and biotechnology companies to save time and money, as they have the expertise and resources to develop and maintain these models.

Academic and research institutions also play an important role in the humanized mouse model market. Academic researchers develop new technologies that can be used to create humanized mouse models, and they also conduct basic research that can help to improve the efficacy and safety of these models. Academic institutions also train the next generation of scientists who will be responsible for developing and using humanized mouse models in the future.

Based on Region:

North America is the largest market for humanized mouse models, accounting for 35% of the global market in 2022. The growth of the market in North America is being driven by the increasing prevalence of chronic diseases, such as cancer and autoimmune diseases. The United States is the largest market for humanized mouse models in North America.

Europe is the second-largest market for humanized mouse models, accounting for 25% of the global market in 2022. The growth of the market in Europe is being driven by the increasing prevalence of chronic diseases, as well as the growing investment in research and development by pharmaceutical and biotechnology companies. Germany, France, and the United Kingdom are the largest markets for humanized mouse models in Europe.

Asia-Pacific is the fastest-growing market for humanized mouse models, accounting for 18% of the global market in 2022. The growth of the market in Asia-Pacific is being driven by the increasing number of research institutions and pharmaceutical companies in the region. China, Japan, and South Korea are the largest markets for humanized mouse models in Asia-Pacific.

Latin America and Middle East & Africa are the smallest markets for humanized mouse models, accounting for 6% and 3% of the global market in 2022, respectively. The growth of the market in these regions is being driven by the increasing investment in research and development by pharmaceutical and biotechnology companies.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Denmark
  • Finland
  • Iceland
  • Sweden
  • Norway
  • Belgium
  • The Netherlands
  • Luxembourg
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Benelux Union
• Rest of Europe
• Asia-Pacific
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Rest of Southeast Asia
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Significant Market Dynamics:

Market Dynamics

The humanized mouse model market is a rapidly growing market, driven by the increasing prevalence of chronic diseases, the growing investment in research and development by pharmaceutical and biotechnology companies, and the advances in technology.

Restraints

The humanized mouse model market is also facing some restraints, such as the high cost of these models, the ethical concerns associated with their use, and the challenges of maintaining these models.

Drivers

The major drivers of the humanized mouse model market include:

• Increasing prevalence of chronic diseases: Chronic diseases, such as cancer, autoimmune diseases, and neurodegenerative diseases, are becoming increasingly prevalent. These diseases are often difficult to study in humans, due to the ethical and logistical challenges involved. Humanized mouse models provide a valuable alternative for studying these diseases.
• Growing investment in research and development: Pharmaceutical and biotechnology companies are investing heavily in research and development, and humanized mouse models are an important tool for this research. Humanized mouse models can help to identify new drug targets, and they can also be used to test the efficacy and safety of new drugs.
• Advances in technology: Advances in technology are making it easier to create and maintain humanized mouse models. For example, new gene editing technologies are making it possible to insert human genes into mouse cells. This is leading to the development of more accurate and reliable humanized mouse models.

Trends

The following are some of the trends that are expected to shape the humanized mouse model market in the coming years:

• Increasing use of humanized mouse models in drug discovery and development: Humanized mouse models are becoming increasingly used in drug discovery and development. These models can help to identify new drug targets, and they can also be used to test the efficacy and safety of new drugs.
• Development of more accurate and reliable humanized mouse models: Advances in technology are making it possible to develop more accurate and reliable humanized mouse models. This is leading to the development of models that can be used to study a wider range of diseases.
• Increased collaboration between pharmaceutical and biotechnology companies and academic institutions: Pharmaceutical and biotechnology companies are increasingly collaborating with academic institutions to develop and use humanized mouse models. This collaboration is essential for the continued growth of the humanized mouse model market.

Challenges

The humanized mouse model market is also facing some challenges, such as:

• High cost of these models: Humanized mouse models are expensive to develop and maintain. This can limit the availability of these models to research institutions and pharmaceutical companies.
• Ethical concerns associated with their use: There are some ethical concerns associated with the use of humanized mouse models. For example, some people argue that it is unethical to use human cells in animals.
• Challenges of maintaining these models: Humanized mouse models can be difficult to maintain. This is because they are susceptible to a variety of diseases and infections.

Opportunity

Despite the challenges, the humanized mouse model market is still a growing market. There is a significant opportunity for companies that can develop and provide high-quality humanized mouse models.

Scope of Report :

Report Attribute	Details
Study Period	2017-2030
Base Year	2022
Estimated year	2023
Forecast period	2023-2030
Historic Period	2017-2022
Units	USD 188.57 Million
Growth Rate	CAGR of  9.54% from 2023 to 2030
By Type	Humanized Mouse Models Humanized Rat Models
By Application	Pharmaceutical & Biotechnology Companies Contract Research Organizations Academic & Research Institutions
By Companies	Ingenious Targeting Laboratory Axen rans Genic Inc. Horizon Discovery Group PLC HuMurine Technologies Champions Oncology Inc. Trans Genic Inc. Crown Bioscience Inc. Others.
Regional Scope	North America Europe Asia-Pacific The Middle East & Africa Latin America
Reasons to Purchase this Report and Customization Scope	6-month post-sale analyst assistance. 10% Free Customization and 15 Company Profiles in addition to the ones specified

Conclusion:
                  The market for humanized mouse models is growing quickly. This is because chronic diseases are becoming more common, pharmaceutical and biotechnology businesses are investing more in research and development, and technology is getting better.
As these trends continue to drive demand for humanized mouse models, the market is likely to keep growing in the coming years. But the market also faces problems, such as the high cost of these models, ethical worries about how they are used, and the difficulty of keeping these models in good shape.
Even with these problems, the market for humanized mouse models is still on the rise. There is a big market for businesses that can make and sell humanized mouse models of high quality.